Pfizer, Inc.

PFE

US7170811035

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:01:05 2024-06-20 pm EDT			5-day change	1st Jan Change
27.74 ^USD	+1.20%		+0.33%	-3.65%

Jun. 18	Global markets live: Shell, UBS, Boeing, Berkshire Hathaway, Exxon...
Jun. 18	Sector Update: Health Care Stocks Flat to Lower Premarket Tuesday	MT

Pfizer : Malawi Ministry of Health, bioMérieux, and Pfizer Form Country’s First Multisectoral Collaboration to Help Address Antimicrobial Resistance

May 23, 2024 at 07:08 am EDT

Malawi Ministry of Health, bioMérieux, and Pfizer Form Country's First Multisectoral Collaboration to Help Address Antimicrobial Resistance Thursday, May 23, 2024 - 07:00am View pdfcopyCopy to clipboardOpen in tab Collaboration will leverage cross-sector resources and expertise to further the Malawi Ministry of Health's work to prevent antimicrobial resistance. [...]

This is an abstract of the document. To keep reading, click here and get access to the original version.

Attachments

Original Link
Permalink

Disclaimer

Pfizer Inc. published this content on 23 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 May 2024 11:07:09 UTC.

Latest news about Pfizer, Inc.

Global markets live: Shell, UBS, Boeing, Berkshire Hathaway, Exxon...	Jun. 18
Sector Update: Health Care Stocks Flat to Lower Premarket Tuesday	Jun. 18	MT
Pfizer Sued by Kansas Over Covid-19 Vaccine	Jun. 18	MT
Certain Ordinary Shares of Haleon plc are subject to a Lock-Up Agreement Ending on 18-JUN-2024.	Jun. 17	CI
Certain American Depositary Shares of Haleon plc are subject to a Lock-Up Agreement Ending on 18-JUN-2024.	Jun. 17	CI
US FDA approves Merck's pneumococcal vaccine for adults	Jun. 17	RE
Kansas accuses Pfizer of misleading public about COVID vaccine in lawsuit	Jun. 17	RE
US FDA puts partial clinical hold on BioNTech's early-stage study of cancer drug	Jun. 17	RE
FDA asks COVID vaccine makers to target KP.2 strain with updated shots	Jun. 14	RE
Pfizer: improved overall survival in myeloma	Jun. 14	CF
Pfizer's Phase 2 MagnetisMM-3 Study of ELREXFIO Shows Median Overall Survival of Over 2 Years	Jun. 14	MT
Pfizer Inc. Announces Detailed Overall Survival Results from the Phase 2 MagnetisMM-3 Study of ELREXFIO	Jun. 14	CI
Health Care Flat on Mixed Drug Developments - Health Care Roundup	Jun. 13	DJ
Global markets live: Shell, Broadcom, Apple, Sony, Apple...	Jun. 13
Pfizer : share price down, Duchenne clinical trial failure	Jun. 13	CF
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	Jun. 13	MT
Only one rate cut this year?	Jun. 13
Pfizer: presents results of treatment for DMD	Jun. 13	CF
Pfizer Prospective Treatment for Duchenne Muscular Dystrophy Fails to Meet Goals	Jun. 12	MT
Pfizer's Duchenne Muscular Dystrophy Treatment Misses Endpoints	Jun. 12	DJ
Pfizer's gene therapy for a muscle-wasting disorder misses main goal of late-stage study	Jun. 12	RE
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with Duchenne Muscular Dystrophy	Jun. 12	CI
Moderna's RSV Vaccine Has 'Ample Opportunity' Despite Seasoned Competitors, Oppenheimer Says	Jun. 12	MT
GSK Starts Appeal Against US State Court Ruling on Zantac Lawsuit	Jun. 11	MT
GSK Starts Appeal Process Against Delaware Court Decision Allowing Expert Testimonies in Zantac Litigation	Jun. 11	MT

Chart Pfizer, Inc.

Duration

Period

More charts

Company Profile

Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (12.1%); - other (1.3%). At the end of 2022, the group had more than 35 manufacturing sites worldwide. Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).

Sector

Pharmaceuticals

Calendar

2024-07-30 - Q2 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Pfizer, Inc: A cycle for nothing?

December 14, 2023 at 10:58 am EST

Albert Bourla, Pfizer CEO (full interview): mRNA, acquisitions, weight-loss drugs

October 31, 2023 at 04:50 pm EDT

More Strategies

Ratings for Pfizer, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

27.74 USD

Average target price

31.92 USD

Spread / Average Target

+15.05%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PFIZER, INC.	-3.65%	155B
ELI LILLY AND COMPANY	+51.99%	803B
JOHNSON & JOHNSON	-5.72%	351B
MERCK & CO., INC.	+18.94%	324B
ABBVIE INC.	+11.07%	303B
ASTRAZENECA PLC	+16.96%	243B
ROCHE HOLDING AG	+2.25%	228B
NOVARTIS AG	+11.15%	217B
AMGEN INC.	+7.59%	164B
SANOFI	-1.84%	117B

Other Pharmaceuticals

Pfizer, Inc.

Equities

PFE

US7170811035

Pharmaceuticals

Pfizer : Malawi Ministry of Health, bioMérieux, and Pfizer Form Country’s First Multisectoral Collaboration to Help Address Antimicrobial Resistance

EPS Revisions